An Early Phase 1 interventional study of D-0120 in combination with Allopurinol in Healthy, sponsored by InventisBio Co., Ltd. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-01.
Sponsored by InventisBio Co., Ltd · Early Phase 1, Interventional, and Other
Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects
InventisBio Co., Ltd is the lead sponsor of 32 studies on the registry; 10 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
D-0120 dosing followed by Allopurinol and combination treatment
Drug: D-0120 in combination with Allopurinol
Allopurinol dosing followed by D-0120 and combination treatment
Drug: D-0120 in combination with Allopurinol
noted above
Type, incidence, severity and attribution of AEs.
Evaluation of safety between D-0120 and Allopurinol
Time frame: 14 days
Plasma concentration of D-0120 and Allopurinol
Evaluation of exposure between D-0120 and Allopurinol
Time frame: 14 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InventisBio Co., Ltd